70% of your immune system lives in your gut - and most people are quietly damaging it without knowing.
Every time you get sick, you probably think about your immune system. You probably don't think about your intestines. But the two are inseparable - and researchers have understood this for decades while the rest of us were still treating the gut as a digestion machine and nothing more.
The figure - 70% of immune cells residing in the gut - is frequently cited and just as frequently misunderstood. It does not mean the gut "is" the immune system. It means that the gut-associated lymphoid tissue (GALT) is the largest single reservoir of immune cells in the body, and that the crosstalk between the luminal microbiome and these immune populations determines, in large part, the inflammatory setpoint of the entire organism.
The anatomy of gut immunity
The GALT comprises several distinct structures: Peyer's patches (lymphoid aggregates in the small intestinal mucosa), isolated lymphoid follicles, the lamina propria (which contains the largest population of IgA-secreting plasma cells in the body), and the intraepithelial lymphocyte layer. These structures are in continuous, dynamic communication with the luminal contents via specialised epithelial cells called M cells, which sample antigens and present them to the underlying immune tissue.
Secretory IgA (sIgA) is the dominant immunoglobulin at mucosal surfaces and is produced at a rate of 3–5 grams per day in healthy adults - more than all other immunoglobulin classes combined. Its primary function is immune exclusion: coating luminal antigens and microorganisms to prevent translocation across the epithelial barrier. Dysbiosis - disruption of microbial community composition - reduces sIgA output, compromising this first line of defence.
The microbiome-immunity axis
The mechanistic link between microbiome composition and systemic immune function operates primarily through two pathways: short-chain fatty acid (SCFA) production and pattern recognition receptor (PRR) signalling.
SCFAs - principally butyrate, propionate, and acetate - are produced by the fermentation of dietary fibre by anaerobic bacteria including Faecalibacterium prausnitzii, Roseburia intestinalis, and Bifidobacterium species. Butyrate is the primary energy source for colonocytes and also acts as a histone deacetylase (HDAC) inhibitor, directly regulating the differentiation of T-regulatory (Treg) cells in the colon. Treg cells suppress excessive inflammatory responses and are essential for immune tolerance - the ability to distinguish self from non-self and commensal bacteria from pathogens.
Reduced SCFA production - caused by low fibre intake, antibiotic exposure, or loss of SCFA-producing species - decreases Treg cell populations, which has been linked to increased susceptibility to autoimmune conditions, allergic disease, and chronic inflammatory states in both animal models and human epidemiological data.
L-Glutamine and barrier integrity
The single-layer epithelial barrier between the gut lumen and the systemic circulation is maintained by tight junction proteins including claudin, occludin, and zonulin. Disruption of these junctions - "leaky gut" in clinical shorthand - permits the translocation of bacterial lipopolysaccharide (LPS) and other immunogenic molecules into the portal circulation, triggering systemic low-grade inflammation via TLR4-NF-κB signalling.
L-Glutamine is the primary fuel for enterocytes and is essential for tight junction synthesis. Multiple RCTs have shown that L-Glutamine supplementation (typically 0.5–2 g/day) significantly reduces intestinal permeability markers including urinary lactulose/mannitol ratio and serum zonulin in populations with compromised barrier function. Our Gut Health formula contains 2 g L-Glutamine - at the upper end of the clinically-studied range.
Probiotic strain selection
Not all probiotic strains interact with immune tissue identically. The evidence for immune modulation is strain-specific, not genus-specific. Lactobacillus rhamnosus GG has the strongest data for reducing upper respiratory tract infection incidence. Bifidobacterium longum BB536 has specific evidence for reducing allergic inflammation markers. A multi-strain formula targeting both Lactobacillus and Bifidobacterium populations with documented colonisation capacity provides broader coverage than single-strain products - which is why our formulation uses a 50B CFU multi-strain complex rather than a single-species approach.
